China has emerged as a leading force in pharmaceutical and medical device innovation, narrowing its gap with the United States.
China is rapidly moving from reliance on generic medicines to a position of strength in innovative drugs and medical equipment, health officials said Thursday.
During a press briefing on the 14th Five-Year Plan, Guo Yanhong of the National Health Commission cited breakthroughs such as Sugemalimab and Ensartinib for lung cancer and Zanubrutinib for blood cancer, now approved internationally. China ranks second globally in new drug development, with its projects accounting for over 20% of the total.
Between January and August, Chinese firms disclosed $84.5 billion in overseas out-licensing deals, nearly half the global figure, including 17 blockbuster agreements. Analysts say Chinese companies excel in innovation and cost control but must strengthen global commercialization and regulatory capacity.
China is also advancing medical devices, unveiling photon-counting CT scanners, surgical robots, and domestically produced ECMO machines. Officials said these innovations offer higher precision, lower costs, and expanded access for patients.